期刊文献+

IA在预防肾移植后超急性排斥反应中的应用观察

Clinical application of immunoadsorption for prevention of hyper acute rejection after renal transplantation
暂未订购
导出
摘要 目的观察葡萄球菌蛋白A免疫吸附(IA)治疗在预防肾移植术后超急性排斥反应(HAR)的疗效,探讨IA治疗方案.方法16例群体反应性抗体(PRA)50%~98%的肾移植患者在术前行IA治疗151人次,每次再生血浆3 000~4 500 mL,强化IA时,每次再生血浆7 500mL,检测每次IA治疗前后血清免疫球蛋白(Ig)、补体(C3、C4)及PRA,追踪患者肾移植术的转归.结果16例患者经IA治疗5~12次后,PRA均降至10%以下(其中3例阴性),Ig、C3、C4均明显下降(P<0.05),肾移植术后均未发生HAR,观察6~12个月经过良好.结论IA能迅速清除患者体内的抗体,降低PRA水平,预防HAR的发生. To observe the effect of immunoadsorption(IA) of staphylococci protein A for the prevention of hyper acute rejection (HAR) after renal transplantation, the suitable regimen, dosage and opportunity of IA were explored. In 16 patients with population reaction antibody (PRA) arranged 50%~98%, IA was carried out 151 times before and after renal transplantation, with actified plasma 3 000~4 500 mL per time, and when intensified, 7 500 mL per time. Immunoglobin(Ig), complement (C3, C4) and PRA were assayed before and after IA therapy. The patients were followed up for systemic conditions and HAR development. After IA treatment of 5~12 times in the 16 patients, PRA was decreased to less than 10%, and in three patients, it was negative. Ig, C3, C4 fallen were more obvious after operation than before (P <0.05). No HAR developed after renal transplantation, and the systemic conditions were good during the follow up period of 6~12 months. [Conclusion] IA therapy can rapidly clear the antibodies in the body, decrease PRA level and prevent HAR.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2005年第5期716-718,共3页 China Journal of Modern Medicine
关键词 肾移植 超急性排斥反应 IA renal transplantation hyper acute rejection immunoadsorption
  • 相关文献

参考文献6

二级参考文献27

  • 1David C, Kluth,Andrew J. Anti-glomerular basement membrane disease. J Am Soc Nephrol, 1999, (10) :2446.
  • 2Lockwood CM, Rees AJ,Pearson TA et al. Immunosuppression and plasma exchage in the treatneat of Goodpasture's syndrome.Lancet, 1976,1:711.
  • 3Pusey CD, Rees AJ, Evans DJ et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int, 1991,40: 757.
  • 4Alan DS,Jeremy BL, Liz L et al. Goodpasture's disease.Lancet,2001,358:917.
  • 5Frank M, Kai-Olaf N, Oliver G et al. Thearapeutic options for critically ill patients suffering frown progressive lupus nephritis or Goodpasture's syndrome.Kidney Int, 1998,53(Suppl 64) :S31.
  • 6Bygren P, Christian F, Tore L et al. Goodpasture's syndrome treated with staphylococcal protein A immunoadsorption. Lancet, 1985,2(8467) : 1295.
  • 7Esnault VL,Testa A, Jayne DR et al. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonepbritis. Nephron, 1993,65 : 180.
  • 8Moreso F, Poveda R, Gil-Vernet S et al. Therapeutic immunoadsorption in Goodpasture disease. Med Clin (Barc), 1995,105(2) :59.
  • 9Klaus L, Sylvia K,Kurt D et al. Immunoadsorption in Goodpasture's syndrome.Am J Kidney Dis,2000,36(2) :392.
  • 10Turner AN, Rees AJ. Antiglomerular basement membrane disease. In:Davison AN, Cameron JS, Grunfeld J-P et al. Oxford Textbook of Nephrology: Oxford University Press, 1998,645.

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部